Literature DB >> 31015906

2,2-Dimethyl-3,4-dihydro-2H-1,4-benzoxazines as isosteres of 2,2-dimethylchromans acting as inhibitors of insulin release and vascular smooth muscle relaxants.

Bernard Pirotte1, Xavier Florence1,2, Eric Goffin1, Philippe Lebrun2.   

Abstract

The present study describes the synthesis and biological evaluation of 4-phenylureido/thioureido-substituted 2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazines as isosteres of corresponding 2,2-dimethylchromans reported to be pancreatic β-cell KATP channel openers. The benzoxazines were found to be less active as inhibitors of the glucose-induced insulin release than their corresponding chromans, while the myorelaxant activity of some 4-arylureido-substituted benzoxazines was more pronounced than that exhibited by their chroman counterparts. The myorelaxant activity of the most potent benzoxazine 8e was further characterized on rat aortic rings precontracted by 30 mM KCl in the presence of glibenclamide (10 μM) or precontracted by 80 mM extracellular KCl. Our findings indicate that, on vascular smooth muscle cells, the benzoxazine 8e mainly behaved as a calcium entry blocker.

Entities:  

Year:  2019        PMID: 31015906      PMCID: PMC6457173          DOI: 10.1039/c8md00593a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  35 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

Review 2.  ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction.

Authors:  Piero Pollesello; Alexandre Mebazaa
Journal:  Curr Opin Crit Care       Date:  2004-12       Impact factor: 3.687

3.  Virtual computational chemistry laboratory--design and description.

Authors:  Igor V Tetko; Johann Gasteiger; Roberto Todeschini; Andrea Mauri; David Livingstone; Peter Ertl; Vladimir A Palyulin; Eugene V Radchenko; Nikolay S Zefirov; Alexander S Makarenko; Vsevolod Yu Tanchuk; Volodymyr V Prokopenko
Journal:  J Comput Aided Mol Des       Date:  2005-06       Impact factor: 3.686

4.  Preclinical pharmacology of Ro 31-6930, a new potassium channel opener.

Authors:  P M Paciorek; D T Burden; Y M Burke; I S Cowlrick; R S Perkins; J C Taylor; J F Waterfall
Journal:  J Cardiovasc Pharmacol       Date:  1990-02       Impact factor: 3.105

Review 5.  KATP channels as molecular sensors of cellular metabolism.

Authors:  Colin G Nichols
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

6.  A potent diazoxide analogue activating ATP-sensitive K+ channels and inhibiting insulin release.

Authors:  P Lebrun; P Arkhammar; M H Antoine; Q A Nguyen; J B Hansen; B Pirotte
Journal:  Diabetologia       Date:  2000-06       Impact factor: 10.122

Review 7.  Function and distribution of the SUR isoforms and splice variants.

Authors:  Nian-Qing Shi; Bin Ye; Jonathan C Makielski
Journal:  J Mol Cell Cardiol       Date:  2005-02-05       Impact factor: 5.000

8.  KATP channel openers: tissue selectivity of original 3-alkylaminopyrido- and 3-alkylaminobenzothiadiazine 1,1-dioxides.

Authors:  Philippe Lebrun; Bénédicte Becker; Nicole Morel; Philippe Ghisdal; Marie-Hélène Antoine; Pascal de Tullio; Bernard Pirotte
Journal:  Biochem Pharmacol       Date:  2007-09-01       Impact factor: 5.858

9.  New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.

Authors:  Xavier Florence; Sophie Sebille; Pascal de Tullio; Philippe Lebrun; Bernard Pirotte
Journal:  Bioorg Med Chem       Date:  2009-09-25       Impact factor: 3.641

10.  4-Phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky 'carbamate' moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion.

Authors:  Bernard Pirotte; Xavier Florence; Eric Goffin; Marlen Borges Medeiros; Pascal de Tullio; Philippe Lebrun
Journal:  Eur J Med Chem       Date:  2016-05-24       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.